From the editor


A more effective jab? F


On the web...


Keep up with the latest developments across the industry by visiting www.worldpharmaceuticals.net


World Pharmaceutical Frontiers 2022 Vol. 1


Editorial Editor Peter Littlejohns peter.littlejohns@progressivemediainternational.com Sub-editor Nikki Peach Production manager Dave Stanford Group art director Henrik Williams Designer Martin Faulkner Head of content Jake Sharp


Commercial Sales manager Nathan Park


nathan.park@progressivemediainternational.com Client services executive Derek Deschamps Managing director William Crocker


World Pharmaceutical Frontiers is published by Progressive Media International.


Registered in England No. 06212740.


40-42 Hatton Garden, London, EC1N 8EB, UK Tel: +44 207 936 6400 www.worldpharmaceuticals.net


ISSN 1742-3791 © 2021


All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of the information in this publication, the publisher accepts no responsibility for errors/omissions.


The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.


Subscription records are maintained at Progressive Media International.


SUBSCRIPTIONS Single issue price: UK £38 EU €59 US $78 RoW $78 One year: Two year:


or the majority of us, Covid-19 has become little more than an afterthought. Mask wearing has dwindled and the common narrative is that the Omicron variant causes symptoms no worse than a common cold. Judging by the opinions of health professionals lending their expertise in the media, this is itself an exaggeration, but more pertinently there are still at-risk populations driving a significant monthly death toll.


In the UK, the number of deaths has actually risen since March after a drop in February, and a Spring booster jab has been recommended for over 75s. But with more evidence mounting to suggest protection from the current vaccines wanes more quickly against Omicron, as it did with Delta, it’s worth asking if we could improve that efficacy. That’s exactly what Monica Karpinski did, and on page 44, she discusses the potential for adjuvants to improve current and future vaccines. Since the early days of deployment, the vaccines have been rejected by some, and on page 10 Mae Losasso explores some of the catalysts behind the behaviour and asks the experts whether an oral alternative would go down better with the unvaccinated.


While Covid has held the headlines for some time now, for those with long- term conditions it’s been an additional risk they have to manage – especially when they could become seriously ill from the virus owing to their vulnerability. Diabetes is one of these conditions, and on page 13 Tim Gunn speaks to Novo Nordisk’s VP of digital health to gain insight into how technology can be combined with drug delivery devices to help diabetics stay on top of their blood sugar levels. Other topics explored in this issue include an expert guide on contamination control in pharmaceutical manufacturing, the value of hybrid containers when temperature control is paramount and why a design-thinking approach is necessary to using glass in drug packaging.


Peter Littlejohns, editor


UK £58 EU €92 US $119 RoW $120 UK £93 EU €144 US $190 RoW $191


Tel: +44 845 155 9607 (local rate) Fax: +44 207 458 4032 Email: cs@progressivemediainternational.com Progressive Media International, Riverbridge House, Ground Floor, South Tower, Anchor Boulevard, Crossways Kent DA2 6SL


Printed by Stephens & George Print Group Images used under licence from Shutterstock.com


For reprint, e-print and licensing enquiries Please contact: Media Licensing Co, The Grange, 3 Waverley Road, Farnham, Surrey, GU9 8BB. Tel: +44 203 773 9320 or email info@medialicensingco.com


World Pharmaceutical Frontiers / www.worldpharmaceuticals.net 3


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53